Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors [Yahoo! Finance]
Verastem, Inc. (VSTM)
Last verastem, inc. earnings: 10/29 04:17 pm
Check Earnings Report
US:NASDAQ Investor Relations:
verastem.com
Company Research
Source: Yahoo! Finance
Initial safety and efficacy results from the trial of VS-7375 by partner GenFleet Therapeutics to be presented at the 2025 ASCO Annual Meeting BOSTON, April 23, 2025 BUSINESS WIRE )--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of VS-7375, an oral KRAS G12D (ON/OFF) inhibitor for clinical evaluation. The Company expects to initiate a Phase 1/2a study in mid-2025 with plans for multiple expansion cohorts, including combinations, in advanced solid tumors, such as pancreatic cancer, colorectal cancer, and non-small cell lung cancer. The Company also announced the acceptance of an abstract, by our partner GenFleet Therapeutics, for rapid oral presentation of the preliminary dose escalation phase of the Phase 1/2 study of VS-7375 (also known as GFH375) conducted by
Show less
Read more
Impact Snapshot
Event Time:
VSTM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VSTM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VSTM alerts
High impacting Verastem, Inc. news events
Weekly update
A roundup of the hottest topics
VSTM
News
- Verastem, Inc. (NASDAQ:VSTM) is favoured by institutional owners who hold 60% of the company [Yahoo! Finance]Yahoo! Finance
- Verastem Oncology to Present at the 8th Annual Evercore Healthcare ConferenceBusiness Wire
- Verastem (NASDAQ:VSTM) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
- Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded WarrantsBusiness Wire
- Verastem Oncology to Present at Upcoming Investor ConferencesBusiness Wire
VSTM
Earnings
- 11/4/25 - Miss
VSTM
Sec Filings
- 12/12/25 - Form 4
- 12/10/25 - Form 144/A
- 12/9/25 - Form 4
- VSTM's page on the SEC website